Preventing Post-Stroke Depression
|Depression Cerebrovascular Accident||Behavioral: Problem Solving Therapy Drug: Escitalopram Other: Placebo|
|Study Design:||Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Outcomes Assessor)
Primary Purpose: Prevention
|Official Title:||Prevention of Post-Stroke Depression - Treatment Strategy|
- Incidence of depressive disorders in the study population [ Time Frame: Measured at baseline, Week 6, and Months 3, 6, 9, 12, and 18 ]
- Functional Independence Measure [ Time Frame: Measured at baseline, at Week 6, and at Months 3, 6, 9, 12, and 18 ]
- Stroke Impact Scale [ Time Frame: Measured at baseline, Week 6, and Months 3, 6, 9, 12, and 18 ]
- Neurocognitive tests of executive functions and speed of information processing [ Time Frame: Measured at baseline and after 12 months ]
|Study Start Date:||September 2002|
|Study Completion Date:||November 2008|
|Primary Completion Date:||November 2008 (Final data collection date for primary outcome measure)|
Experimental: 1 Problem Solving Therapy
Participants will receive problem solving therapy.
Behavioral: Problem Solving Therapy
Problem solving therapy aims to make patients aware of symptoms of problems and link those with behaviors associated with solving them.
Experimental: 2. Escitalopram
Participants will receive escitalopram.
Participants will receive escitalopram, a selective serotonin reuptake inhibitor.
Other Name: Lexapro
Placebo Comparator: 3 Placebo
Participants will receive placebo.
Participants will receive a placebo pill.
The development of depression after a stroke is a serious condition that can have negative effects on thought, emotions, and overall daily functioning, particularly in the first year following the stroke. Evidence suggests that antidepressants may be used to prevent post-stroke depression. This study will treat nondepressed stroke patients with antidepressants or problem solving therapy (PST) to determine the most effective treatments for preventing depression.
Participants in this study will be randomly assigned to receive PST, escitalopram, or placebo (an inactive pill) for 12 months. Participants who display depressive symptoms for 2 weeks or more will be removed from the study. After 12 months, treatment will be discontinued and participants will be monitored for an additional 6 months.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00071643
|United States, Illinois|
|University of Chicago|
|Chicago, Illinois, United States, 60637|
|United States, Iowa|
|University of Iowa Hospitals and Clinics|
|Iowa City, Iowa, United States, 52242-1000|
|United States, New York|
|Burke Rehabilitation Hospital|
|White Plains, New York, United States, 10605|